Decreased Plasma Levels of Active Glucagon-Like Peptide-1 in Coronary Artery Disease  by Akiyama, Eiichi et al.
J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y V O L . 6 5 , N O . 7 , 2 0 1 5
ª 2 0 1 5 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 0 7 3 5 - 1 0 9 7 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C .LettersDecreased Plasma Levels
of Active Glucagon-Like
Peptide-1 in Coronary
Artery DiseaseGlucagon-like peptide-1 (GLP-1) is an incretin hor-
mone and has cardiovascular protective effects (1).
Vascular cells express GLP-1 receptors, and studies
have demonstrated that enhancing GLP-1 activity
exhibits beneﬁcial effects on atherosclerosis in ani-
mal models (2). However, the impact of endogenously
secreted GLP-1 on coronary artery disease (CAD) has
not been clinically examined. The aim of this study
was to investigate the associations between plasma
active GLP-1 (aGLP-1) levels, CAD, and coronary pla-
que complexity during fasting or during a 75 g oral
glucose tolerance test (75g-OGTT).
We describe a cross-sectional observational study
(Plasma Levels of Active Glucagon-Like Peptide-1
and Coronary Artery Disease; UMIN000008881)
measuring plasma aGLP-1 levels (Glucagon-Like
Peptide-1 [Active] enzyme-linked immunosorbent
assay, Millipore Corporation, Massachusetts) from a
peripheral vein during fasting or a 75g-OGTT in 236
stable CAD patients (68  10 years of age, 68% male,
32% diabetes mellitus [DM]) who underwent coronary
angiography at Kumamoto University Hospital be-
tween April 2009 and August 2011. These patients
were compared with 97 non-CAD patients of similar
age and sex distribution with a high-risk condition
(DM, or more than 2 conventional coronary risk fac-
tors) during the same study period (DM: 16%). The
75g-OGTT was performed in all patients without overt
DM. We assessed coronary plaque complexity using
the SYNTAX (Synergy between Percutaneous Coro-
nary Intervention with Taxus and Cardiac Surgery)
score in CAD patients.
Fasting active GLP-1 (F-aGLP-1) levels were not
detectable (<2 pmol/l) in a higher percentage of CAD
patients compared to non-CADpatients (n¼ 71, 30%vs.
n¼ 10, 10%; p<0.001). In patients whose fasting active
GLP-1 levels were detectable, fasting GLP-1 levels were
signiﬁcantly lower in CAD patients (n ¼ 165) thanin non-CAD patients (n ¼ 87) (3.2 [2.6 to 4.2] pmol/l vs.
3.8 [2.8 to 5.4] pmol/l; p ¼ 0.001).
We divided all participants (n ¼ 333) into tertiles of
F-aGLP-1 levels (cutoff points: lowest, <2.3 pmol/l;
middle, 2.3 to 3.5 pmol/l; highest, >3.5 pmol/l). The
prevalence of CAD decreased across tertiles (lowest:
n ¼ 94, 85%; middle: n ¼ 84, 73%; highest: n ¼ 58,
54%; p < 0.001). Stepwise backward multivariate
logistic regression analysis, including various clas-
sical risk factors (e.g., DM) demonstrated that
F-aGLP-1 levels were independently associated with
the presence of CAD (per tertile decrease; odds ratio
[OR]: 2.44; 95% conﬁdence interval [CI]: 1.73 to 3.45;
p < 0.001) (c statistic without F-aGLP-1: 0.659; with
F-aGLP-1: 0.753).
In 242 patients without overt DM (CAD: n ¼ 161),
F-aGLP-1 levels were still independently associated
with the presence of CAD (per tertile decrease,
OR: 2.16; 95% CI: 1.47 to 3.19; p < 0.001). The
75g-OGTT identiﬁed patients with newly diagnosed
DM (n ¼ 38, 16%), impaired glucose tolerance (n ¼ 77,
32%), and normal glucose tolerance (NGT) (n ¼ 127,
52%). Even in patients with NGT, F-aGLP-1 levels
independently correlated with the presence of CAD
(per tertile decrease, OR: 2.27; 95% CI: 1.32 to 3.89;
p ¼ 0.003).
Plasma glucose levels and insulin levels during
75g-OGTT were comparable between the 2 groups.
However, levels of aGLP-1 during 75g-OGTT were
signiﬁcantly lower in CAD patients than in non-CAD
patients (Figure 1). Using forced inclusion models
with age, sex, the presence of hypertension, dyslipi-
demia, and metabolic syndrome in the multivariate
logistic regression analysis, F-aGLP-1 and aGLP-1 at
60 min and 120 min during 75g-OGTT but not aGLP-1
at 30 min or peak aGLP-1 were independently asso-
ciated with the presence of CAD in patients without
overt DM (C statistic without aGLP-1: 0.684; with F-
aGLP-1: 0.745; aGLP-1 at 30 min: 0.694; 60 min: 0.712;
120 min: 0.725; peak: 0.687). F-aGLP-1 had the best
model ﬁts, as assessed by Nagelkerke R2.
Of the 236 CAD patients, 54 (23%) showed severe
coronary plaque complexity (SYNTAX score $33).
Multivariate logistic regression analysis demon-
strated that F-aGLP-1 levels were independently
associated with the presence of severe coronary pla-
que complexity (per tertile decrease, OR: 1.65; 95% CI:
FIGURE 1 Active GLP-1 Levels During 75g-OGTT in
Non–Diabetes Mellitus Patients With or Without CAD
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Values are calculated as the mean  SD. CAD ¼ coronary artery
disease; GLP-1 ¼ glucagon-like peptide-1; OGTT ¼ oral glucose
tolerance test.
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7551.08 to 2.54; p ¼ 0.02) (C statistic without F-aGLP-1:
0.664; with F-aGLP-1: 0.705).
The present study is the ﬁrst to demonstrate
signiﬁcantly reduced plasma aGLP-1 levels in a fasting
state and during 75g-OGTT in CAD patients. Lower
aGLP-1 levels were signiﬁcantly correlated with the
presence of CAD. Furthermore, lower F-aGLP-1 levels
were associated with severe coronary plaque
complexity in CAD patients. These results suggested
that there may be a pathophysiological link between
endogenous aGLP-1 and CAD.
Although previous reports have demonstrated that
incretin-related drugs attenuated the development of
atherosclerotic lesions in animal models (2), a large
clinical study failed to demonstrate any beneﬁt of
dipeptidyl peptidase-4 inhibition on ischemic events
in patients with established disease (3). Further
studies are warranted to clarify clinical signiﬁcance of
GLP-1 in CAD.
In summary, plasma aGLP-1 levels were signiﬁ-
cantly reduced in CAD patients, and lower plasma
aGLP-1 levels were independently correlated with
the presence of CAD and coronary plaque com-
plexity. The gut-derived endogenous aGLP-1 may
have a signiﬁcant association with human coronary
atherosclerosis.Eiichi Akiyama, MD
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1317–26.Inﬂuence of Sex
on Mortality and
Perioperative Outcomes
in Patients Undergoing TAVRInsights From the FRANCE 2 RegistryTranscatheter aortic valve replacement (TAVR) is an
alternative to surgery for high-risk or inoperable pa-
tients (1). However, few data, with varied and
confusing follow-up timings, are available (2,3)
